Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Oncological Outcomes and Long-Term Survival among Patients with Gastric Cancer and Limited Peritoneal Disease Progression after Neoadjuvant Chemotherapy.
Sebastian KobiałkaKatarzyna SędłakZuzanna PelcRadosław MlakYutaka EndoPaweł BogaczAndrzej KurylcioWojciech P PolkowskiTimothy M PawlikKarol Rawicz-PruszyńskiPublished in: Journal of clinical medicine (2023)
Data from the current study demonstrated a lack of survival benefit among advanced GC patients with PM undergoing gastrectomy with CRS+HIPEC when compared with individuals after gastrectomy with CRS alone. Administration of perioperative chemotherapy and achievement of TO failed to withstand the peritoneal disease progression during NAC.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- lymph node
- transcription factor
- particulate matter
- air pollution
- electronic health record
- cardiac surgery
- patients undergoing
- heavy metals
- radical prostatectomy
- artificial intelligence
- risk assessment
- big data
- early stage
- acute kidney injury
- chemotherapy induced
- metabolic syndrome
- water soluble
- mass spectrometry
- deep learning
- adipose tissue
- skeletal muscle